Screening And Identification Of Specific Binding Peptides For Human Lymphoma Cell Jeko-1

Malignant lymphoma(ML)is one of the most common hematology malignanciesand is a malignant tumor of the lymphatic system.ML is divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma two types in clinic,whilenon-Hodgkin lymphoma(non-Hodgkin lymphoma,NHL)hasthe highest incidence.Tumor metastasis,recurrence and chemo-resistance are key factors in the poor prognosis of lymphoma.It is important to explore new methods of diagnosis and treatment of lymphoma.In recent years,targeted delivery system for the treatment of lymphoma has received much attention,but no specific,high-affinity carrier has been found at present.Using phage display technology,peptides that specifically bind to tumor cells can be screened.Peptide molecules extracted by biopanning can be used as diagnostic labels for tumor cells and can be coupled with chemotherapeutics as targeted drugs.We directly incubated the phage display library with the target cells while the human lymphoma cell Jeko-1 was used as screening target.After four rounds of biopanning,the phage clones were picked randomly for sequencing and finally the peptide TUZG12 was screened.Further research results showed that the peptide TUZG12 can specifically bind to the lymphoma cell Jeko-1 and had a certain binding ability to the other three lymphoma cells P815,Raji,Su-4 at the same time,whilelymphoma cell Romas and Granta-519 and human normal lymphocytes had no binding activity.These results demonstrated that the peptide TUZG12 had better specificity and selectivity with target cells.We coupled the polypeptide TUZG12 with the proapoptotic peptide D(KLAKLAK)2.Cell viability experiments showed that the conjugated peptide had the ability to inhibit the proliferation of Jeko-1 cells.The IC50 value was 1/3 of the random peptide conjugator.The peptide TUZG12 can be used as a carrier to mediate proapoptotic peptides into Jeko-1 cells and reduce cell viability.In order to improve the stability of the polypeptide in vivo,we synthesized the D-type reversed-molecule of peptide TUZG12.Studies have shown that the D-reverse-peptide also has cell-binding selectivity.Finally,the co-immunoprecipitation technology was used to capture the target molecule bound to tumor cells by TUZG12.In summary,we used phage display technology to biopan human Lymphoma cell Jeko-1-binding Peptides,which is expected to serve as a targeted diagnostic and therapeutic carrier for lymphoma.